Caitlin John’s Emergent Biosolutions EBS Stock Holding History

Caitlin John’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200	Closed	-$1.91K	–	300
2024 Q4	$1.91K	Hold	200	–	–	﹤0.01%	669
2024 Q3	$1.99K	Buy	+200	New	+$1.82K	﹤0.01%	661

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caitlin John's EBS Position: Q1 2025 in Review

Caitlin John sold out of Emergent Biosolutions (EBS) in Q1 2025, closing a stake of 1,350 shares — an estimated $12.9K sold.

Caitlin John first reported a position in EBS in Q3 2024 and held it in 2 quarters. The position peaked at $12.9K in Q4 2024. 160 funds tracked by Wall St. Rank hold EBS as of Q1 2025.

Caitlin John reported no remaining Emergent Biosolutions position as of Q1 2025 after selling out during the quarter.
Caitlin John sold 1,350 Emergent Biosolutions shares in Q1 2025, an estimated $12.9K.
Caitlin John first reported a position in Emergent Biosolutions in Q3 2024 and held it in 2 quarters.
Caitlin John's Emergent Biosolutions position peaked at $12.9K in Q4 2024.
160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2025.

Based on Caitlin John's 13F filing for Q1 2025, filed 14 May 2025.